The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.

Acesion Pharma ("Acesion" or "the Company"), a biotech company pioneering treatments for atrial fibrillation ("AF"), the most common cardiac arrhythmia, today announces enrolment of the first patients ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Implantable ...

May 10, 2005 (New Orleans) – Implantable loop recorders successfully provided a diagnosis in almost half of patients with unexplained syncope or presyncope, New York researchers reported at the Heart ...

Doctors at Columbus Community Hospital now have a high-tech new tool that can help them diagnose irregular heart rhythms that may not show up during standard testing. The tool, called a cardiac loop ...

Please provide your email address to receive an email when new articles are posted on . Implantable loop recorder screening for atrial fibrillation did not significantly reduce the risk for stroke ...

Dublin, Aug. 26, 2020 (GLOBE NEWSWIRE) -- The "Global Implantable Loop Recorders Market By Application (Atrial fibrillation, Cardiac Arrhythmia and Cardiac syncope), By End User (Hospitals, Cardiac ...

Barcelona, Spain, 1 September 2009: The REVISE Study (Reveal in the Investigation of Syncope and Epilepsy) found that 1 in 8 adult patients in the United Kingdom, previously thought to be suffering ...

Please provide your email address to receive an email when new articles are posted on . An artificial intelligence-based ECG analysis solution reduced the rate of false-positive atrial fibrillation ...

The Baylor Medicine Cardiac Electrophysiology team provides the latest diagnosis and treatments for cardiac arrhythmias, including pacing techniques: His-bundle and left bundle pacing. We are ...

DUBLIN--(BUSINESS WIRE)--The "Global Implantable Loop Recorders Market By Application (Atrial fibrillation, Cardiac Arrhythmia and Cardiac syncope), By End User (Hospitals, Cardiac Centers and Other ...

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.